Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Fractyl Health, Inc. ( (GUTS) ).
On June 11, 2025, Fractyl Health, Inc. held its Annual Meeting of Stockholders, with approximately 70.38% of the company’s common stock voting power represented. During the meeting, William W. Bradley, Ajay Royan, and Amy W. Schulman were elected as Class I directors for a three-year term, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (GUTS) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.
Spark’s Take on GUTS Stock
According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.
Fractyl Health’s overall stock score reflects substantial financial challenges and a negative valuation, which are offset by strong technical momentum and promising clinical progress. Recent corporate events point to potential future growth opportunities, though the financial instability and limited cash reserves remain significant risks.
To see Spark’s full report on GUTS stock, click here.
More about Fractyl Health, Inc.
Average Trading Volume: 297,693
Technical Sentiment Signal: Buy
Current Market Cap: $105.8M
See more insights into GUTS stock on TipRanks’ Stock Analysis page.